With emraclidine failing to progress to Phase 3, I would agree that AbbVie possesses one of the less impressive late-stage pipelines among Big Pharmas, and that its R&D investments - certainly ...

Shares in AbbVie have slumped after a pair of failed phase 2 trials for emraclidine, a schizophrenia drug it acquired as part of its $8.7 billion takeover of Cerevel Therapeutics last year.

Neurocrine's drug acts as a muscarinic M4 selective agonist, while KarXT targets M1 and M4 receptors and emraclidine is described as a muscarinic M4 receptor-positive allosteric modulator (PAM).

Reuters.com is your online source for the latest Middle-East news stories and current events, ensuring our readers up to date with any breaking news developments ...

Follow the latest Immigration news stories and headlines. Get breaking news alerts when you download the ABC News App and subscribe to Immigration notifications.

Find latest cybersecurity news from every corner of the globe at Reuters.com, your online source for breaking international news coverage.

Honolulu Star-Advertiser is Hawaii's source for local news headlines and editorial columns. Call 538-NEWS (6397) to subscribe today.

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

The latest international news, investigations and analysis from Africa, the Americas, Asia, Australia, Canada, Europe, the Middle East and the U.K.

Today's Duluth news and coverage from Duluth, BWCA, Grand Marais, North Shore and the Iron Range from the Minnesota Star Tribune.

The artificial intelligence application has led to $9.3 million in claims paid that might have been denied. What's more, the tech has resulted in $871,000 in new revenue for Medicare Severity ...